XCUR:NASDAQExicure, Inc. Analysis
Data as of 2026-08-01 - not real-time
$1.60
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Exicure, Inc. is trading well below its short‑term moving averages, with technical indicators pointing to a bearish momentum and shrinking volume. The MACD histogram has turned positive but the line remains under the signal, suggesting only a tentative lift that lacks conviction. Fundamentals are stark: the company reports no revenue, negative earnings per share and cash burn that far exceeds its cash balance, while operating cash flow remains deeply negative. Volatility is extremely high and the beta is below market, indicating price swings that are not closely tied to broader market moves. Recent material news highlights a Nasdaq compliance notice over equity requirements and a board reshuffle, underscoring governance and listing‑status concerns. Overall, the stock appears overvalued relative to its financial reality and faces multiple risk layers.
Given the extreme greed sentiment in the market, investors may be tempted by speculative upside, yet the lack of operating traction, cash constraints and regulatory pressures suggest that any upside is highly uncertain. The combination of a tiny market cap, decreasing liquidity and a sector known for binary outcomes makes the investment profile more akin to a distressed speculative play than a growth story.
Given the extreme greed sentiment in the market, investors may be tempted by speculative upside, yet the lack of operating traction, cash constraints and regulatory pressures suggest that any upside is highly uncertain. The combination of a tiny market cap, decreasing liquidity and a sector known for binary outcomes makes the investment profile more akin to a distressed speculative play than a growth story.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- Bearish technical positioning and decreasing volume
- Negative earnings and cash burn outpacing cash reserves
- Nasdaq listing compliance issue
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential for partnership upside with existing co‑development agreement
- Continued high volatility may create price swings
- Fundamental fundamentals remain weak with no revenue
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Biotech sector’s long‑term binary risk profile
- Uncertainty around future financing or acquisition
- Persistently negative cash flow and lack of operating traction
Key Metrics & Analysis
Financial Health
P/E Ratio-2.1
ROE-145.16%
ROA-32.51%
Debt/Equity1.05
P/B Ratio4.9
Op. Cash Flow$-8099000
Free Cash Flow$-3878000
Industry P/E29.2
Technical Analysis
TrendBearish
RSI36.2
Support$1.43
Resistance$2.10
MA 20$1.75
MA 50$2.31
MA 200$3.93
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta0.62
Volatility107.29%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.